(Source: China Times 2015-01-14）
TCMBio announced that the company has obtained the marketing authorization for PTX 9908, a new drug developed by Beijing-based Microconstants for mid-stage liver cancer.
TCMBio will pay a total of US$3 million for the marketing authorization in the Great China region. Mr. Ya-Jun Wang, the General Manager of TCMBio, expressed that PTX 9908 is a polypeptide drug. It has already completed Phase I clinical trials in Europe and Phase I/II clinical trials in North America. The developer plans to apply for phase II clinical trials in the US and Taiwan in the first half of 2015.
Wang expressed that phase II clinical trials will focus on the concomitant use of Liver Transarterial Chemoembolization (TACE) and PTX 9908 on patients with liver cancer. Phase III clinical trials will be multi-center trials conducted in Macao, Hong Kong and China. The new drug, after approved by the health authorities, will be available in Taiwan through importation.
TCMBio focuses its R&D on botanic drugs. The company’s revenue in 2014 was NT$320 million, up by 8%.
Beijing-based Microconstants recently signed the marketing authorization of PTX 9908 in the Great China region, including Taiwan, China, Hong Kong and Macao, to TCMBio. The upfront payment will be under US$100,000, and the total payment for licensing will be around US$ 3 million.
(Translated by TRPMA)
More Information on China Times